Biomedical Research Foundation Academy Of AthensAcademy Of Athens
Scientific Personnel

Dimitrios Dimitrios Roukos, MD, PhD
University Faculty, Affiliated Investigator

Center :

Systems Biology

Brief Bio

Dimitrios H. Roukos, MD, PhD, is Professor of Surgery – Precision Cancer Medicine and Founding director of “Centre for Biosystems and Genome Network Medicine” in the Ioannina University, School of Medicine. Following conventional surgical oncology research, he has shifted into interpatient heterogeneity-based Personalized Cancer Medicine combining clinico-pathologic and single gene characteristics. Recently, he is exclusively focusing on intratumor multi-regional and even single-cell genetic, genomic, transcriptional and regulatory network heterogeneity-based drug resistance and relapse towards future clinical Precision Oncology. He has developed and published 3 breakthrough concepts to overcome clinical unmet needs.
He has published > 240 PubMed papers, 36 on Precision Medicine and Oncology, and 80 on static and spatiotemporal genome analysis with NGS. These publications have received more than 9000 citations with h-index: 75 (Scopus). He is reviewer in many high impact journals including some with impact factor (IF) >30, evaluator in innovative research projects (EU, France, Italy, Belgium, Luxemburg, Poland), member in the editorial board of 25 international journals with IF, as well as Organizing Committee member and Invited lectures in > 130 International Conferences.

Selected Publications

Kyrochristos ID, Ziogas D, Roukos DH. Drug resistance: origins, evolution and characterization of genomic clones and tumor ecosystem to optimize precise individualized therapy. Drug Discovery Today (accepted manuscript). 2019.

Kyrochristos ID, Ziogas DE, Roukos DH. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. Medicinal research reviews. 2018

Ziogas DE, Kyrochristos ID, Roukos DH. Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. Drug discovery today. 2018;23(11):1848-1872

Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Drug discovery today. 2017;22(8):1148-1164.

Roukos DH. Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies. Drug discovery today. 2016;21(4):663-673.

Kyrochristos et al From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers Int J Mol Sci. 2017 Jan 18;18(1). pii: E180. doi: 10.3390/ijms18010180.

Kyrochristos ID, Ziogas DE, Antoniou P, Mitsis M, Lykoudis EG, Roukos DH. Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. Pharmacogenomics. 2018 Nov;19(17):1303-1310. doi: 10.2217/pgs-2018-0141. 

Lianos GD, Glantzounis GK, Bali CD, Katsios C, Roukos DH. Identification of novel genes by whole-exome sequencing can improve gastric cancer precision oncology, Future Oncol. 2017 Apr;13(10):883-892. doi: 10.2217/fon-2016-0430.

Roukos DH, Katsios C, Liakakos T Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn. 2010 Jul;10(5):541-5. doi: 10.1586/erm.10.49.


PubMed Link